



The Illinois Medical Bulletin



The Role of B-Type Natriuretic Peptide Testing in the Diagnosis and Prognosis of Acute Heart Failure: A Review of Foundational Evidence

¹A. Chamberlain, ²A. Cher

^{1,2} University of Illinois College of Medicine

Corresponding Email : chamberlain284883@gmail.com

Article History :

Received date : 2020/10/12
Revised date : 2020/11/28
Accepted date : 2020/12/09
Published date : 2021/01/13



Copyright: © by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (<https://creativecommons.org/licenses/by-nc/4.0/>).

ABSTRACT

Introduction: The clinical assessment of patients presenting with acute dyspnea is a frequent and often complex challenge, with the differentiation of acute decompensated heart failure (ADHF) from other etiologies being critical. The cardiac neurohormones B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP), which are released in response to myocardial stress, were investigated as potential biomarkers to aid in this dilemma.

Literature Review: A review of the pivotal scientific literature reveals the transformative impact of natriuretic peptide testing on the management of heart failure. A landmark, large-scale, multinational prospective study definitively established that measuring plasma BNP levels significantly improved the accuracy of diagnosing ADHF in the emergency department setting. Subsequent large studies confirmed these findings for NT-proBNP. Beyond their diagnostic utility, a substantial body of evidence from numerous cohort studies demonstrated that natriuretic peptide levels are powerful and independent predictors of adverse outcomes. Elevated admission and discharge levels of BNP or NT-proBNP were consistently shown to be strongly associated with increased short- and long-term risk of mortality and rehospitalization.

This robust evidence base led to the rapid integration of natriuretic peptide testing into major international clinical practice guidelines.

Conclusion: The body of work reviewed confirms that natriuretic peptide measurement is an essential tool in the evaluation of patients with suspected ADHF. It provides rapid, objective information that enhances diagnostic accuracy, offers powerful prognostic insights, and has become a standard of care in modern cardiovascular medicine.

Keywords: Heart Failure, B-type Natriuretic Peptide (BNP), NT-proBNP, Dyspnea, Diagnosis, Prognosis.

INTRODUCTION

Acute dyspnea is one of the most common reasons for emergency department visits and hospital admissions. The differential diagnosis is broad, spanning a wide range of cardiac, pulmonary, and other systemic diseases. One of the most critical and difficult diagnostic distinctions to make is between acute decompensated heart failure (ADHF) and non-cardiac causes of breathlessness, such as chronic obstructive pulmonary disease exacerbations or pneumonia. Traditional diagnostic tools, including physical examination, chest radiography, and electrocardiography, can often be inconclusive, leading to diagnostic uncertainty and delays in appropriate therapy.

This clinical challenge spurred the search for a more objective and specific biomarker for heart failure. A highly promising class of candidates was the natriuretic peptides. B-type natriuretic peptide (BNP) and its biologically inert but more stable N-terminal fragment, N-terminal pro-BNP (NT-proBNP), are neurohormones synthesized in and released from the cardiac ventricles in direct response to increased myocardial wall stress and pressure overload. This direct link to the core hemodynamic pathophysiology of heart failure made them ideal targets for investigation. This literature review will synthesise the pivotal evidence that established natriuretic peptide testing as a cornerstone of the modern evaluation of patients with suspected ADHF.

LITERATURE REVIEW

The validation of natriuretic peptides as essential clinical tools was driven by a series of high-impact studies that definitively established their diagnostic and prognostic utility.

The most influential study to establish the diagnostic role of BNP was the landmark Breathing Not Properly Multinational Study. This large, prospective trial enrolled over 1,500 patients presenting to the emergency department with acute dyspnea. The study was designed to assess whether the addition of a rapid, point-of-care BNP measurement improved the accuracy of the physician's clinical judgment in diagnosing ADHF. The results were definitive. The study found that BNP levels were markedly higher in patients whose final diagnosis was ADHF compared to those with non-cardiac causes of dyspnea. The use of a single BNP cutoff value of 100 pg/mL was shown to have a high diagnostic accuracy, and incorporating the BNP result significantly improved the ability of clinicians to correctly identify or exclude the presence of ADHF (Maisel et al., 2002). Similar large-scale studies, such as the PRIDE study, subsequently confirmed a comparable high diagnostic utility for the NT-proBNP assay (Januzzi et al., 2005).

Beyond their immediate diagnostic value, an equally important role for natriuretic peptides emerged in risk stratification and prognostication. A substantial body of evidence from numerous cohort studies consistently demonstrated that the magnitude of the natriuretic peptide elevation was a powerful, independent predictor of future adverse events. Studies analyzing large patient registries, such as the ADHERE registry, showed a clear, graded relationship: the higher the admission BNP level, the higher the in-hospital mortality risk (Fonarow et al., 2005). This prognostic power was not limited to the acute hospital stay. An influential study demonstrated that the BNP level measured at the time of hospital discharge was an even more powerful predictor of subsequent mortality and rehospitalization than the admission level. A high discharge BNP signified persistent hemodynamic stress and identified a patient at very high risk for near-term relapse (Harrison et al., 2002).

The overwhelming and consistent evidence for both the diagnostic and prognostic utility of these biomarkers led to their rapid and widespread adoption into clinical practice. Major cardiovascular societies, including the American College of Cardiology/American Heart Association and the European Society of Cardiology, swiftly incorporated the measurement of BNP or NT-proBNP into their evidence-based clinical practice guidelines for the diagnosis and management of heart failure, giving it their strongest class of recommendation (Hunt et al., 2005).

CONCLUSION

The pivotal literature on B-type natriuretic peptide testing represents a major advance in cardiovascular diagnostics. A landmark trial provided unequivocal evidence that the measurement of BNP is a powerful tool that significantly improves the clinician's ability to accurately and rapidly diagnose acute decompensated heart failure in the challenging setting of the undifferentiated dyspneic patient.

Furthermore, a robust body of evidence established natriuretic peptide levels as one of the most powerful available predictors of short- and long-term outcomes, including mortality and rehospitalization. This research fundamentally changed clinical practice, transforming the evaluation of acute heart failure by providing a simple, objective, and highly informative blood test. The integration of BNP and NT-proBNP testing into routine care has become a global standard, improving diagnostic certainty and enhancing the ability to risk-stratify patients with this common and serious condition.

REFERENCES

- Fonarow, G.C., Adams, K.F., Jr., Abraham, W.T., Yancy, C.W. and Boscardin, W.J. (2005) 'Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis', *JAMA*, 293(5), pp. 572-580.
- Harrison, A., Morrison, L.K., Krishnaswamy, P., Kazan, P., Clopton, P. and Maisel, A. (2002) 'B-type natriuretic peptide predicts future events in patients with decompensated congestive heart failure', *Journal of the American College of Cardiology*, 39(1), pp. 131-138.
- Hunt, S.A., Abraham, W.T., Chin, M.H., Feldman, A.M., Francis, G.S., Ganiats, T.G., Jessup, M., Konstam, M.A., Mancini, D.M., Michl, K., Oates, J.A., Rahko, P.S., Silver, M.A., Stevenson, L.W. and Yancy, C.W. (2005) 'ACC/AHA Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines', *Circulation*, 112(12), pp. e154-e235.
- Januzzi, J.L., Jr., Camargo, C.A., Anwaruddin, S., Baggish, A.L., Chen, A.A., Krauser, D.G., Tung, R., Cameron, R., Nagurney, J.T., Chae, C.U., Lloyd-Jones, D.M., Brown, D.F., Foran-Melanson, S., Sluss, P.M., Lee-Lewandrowski, E. and Lewandrowski, K.B. (2005) 'The N-terminal Pro-B-Type Natriuretic Peptide in the Emergency Department (PRIDE) study', *The American Journal of Cardiology*, 95(8), pp. 948-954.

Maisel, A.S., Krishnaswamy, P., Nowak, R.M., McCord, J., Hollander, J.E., Duc, P., Omland, T., Storrow, A.B., Abraham, W.T., Wu, A.H., Clopton, P., Steg, P.G., Westheim, A., Knudsen, C.W., Perez, A., Kazan, P. and Herrmann, H.C. (2002) 'Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure', *New England Journal of Medicine*, 347(3), pp. 161-167.